Evolent Health (EVH) EBITDA (2015 - 2026)

Evolent Health's EBITDA history runs 12 years deep, the most recent figure standing at -$27.6 million for Q1 2026.

• In Q1 2026, EBITDA rose 61.74% year-over-year to -$27.6 million; the TTM figure through Mar 2026 stood at -$535.7 million (down 280.18% YoY), while the FY2025 annual figure was -$580.3 million, down 517.64% from the prior year.
• EBITDA was -$27.6 million for Q1 2026 at Evolent Health, up from -$429.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.9 million in Q3 2022 to a low of -$429.4 million in Q4 2025.
• Historically, EBITDA has averaged -$50.8 million across 5 years, with a median of -$27.6 million in 2026.
• The sharpest annual moves came in 2022 and 2023: EBITDA jumped 114.28% in 2022, then tumbled 1891.89% in 2023.
• A 5-year view of EBITDA shows it stood at -$11.5 million in 2022, then plunged by 260.42% to -$41.4 million in 2023, then gained by 25.09% to -$31.0 million in 2024, then plunged by 1285.05% to -$429.4 million in 2025, then soared by 93.56% to -$27.6 million in 2026.
• The last three EBITDA figures came in at -$27.6 million (Q1 2026), -$429.4 million (Q4 2025), and -$27.6 million (Q3 2025), per Business Quant data.